DEFENSE-PFO Model (Cryptogenic Stroke Benefit) Calculator

Clinical calculation support · Verify results before clinical use

Patient and PFO anatomy

Enter the transesophageal echocardiography findings to check whether the anatomy matches the high-risk definition used in DEFENSE-PFO.

3 featuresHigh-risk screen

Age is documented for clinical context. Age alone is not a DEFENSE-PFO high-risk anatomical criterion.

Atrial septal aneurysm (ASA) present?

DEFENSE-PFO high-risk threshold: septal excursion ≥10 mm.

DEFENSE-PFO high-risk threshold: maximum separation ≥2 mm.

Reset

Clinical context

The DEFENSE-PFO randomized trial compared transcatheter PFO closure plus medical therapy with medical therapy alone in patients with cryptogenic ischemic stroke and high-risk PFO morphology assessed by transesophageal echocardiography.

High-risk anatomical features

FeatureThreshold used
Atrial septal aneurysmPresent
Septal hypermobilityPhasic excursion ≥10 mm
Large PFO separationMaximum septum primum–secundum separation ≥2 mm

Trial outcomes at 2 years

OutcomeMedical therapyPFO closure
Ischemic stroke10.5%0%
Primary composite endpoint12.9%0%

Trial estimates are based on 120 randomized patients and should be interpreted with the study's sample size, follow-up, population selection, and uncertainty in mind.

References

Lee PH, Song JK, Kim JS, et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018;71(20):2335–2342. DOI: 10.1016/j.jacc.2018.02.046. PMID: 29544871.
Kwon H, Kim BJ, Lee PH, et al. Patent Foramen Ovale Closure in Old Stroke Patients: A Subgroup Analysis of the DEFENSE-PFO Trial. J Stroke. 2021;23(2). This post-hoc subgroup evidence should be interpreted cautiously; complete bibliographic details were not independently confirmed during this update.
Kent DM, et al. Heterogeneity of Treatment Effects in PFO Closure Trials and the PASCAL Classification. JAMA. 2021;326(12). Refer to the original publication for causal-likelihood classification details.
Clinical disclaimer: This tool supports anatomical screening and summarizes trial-level results. It does not diagnose PFO-associated stroke, calculate an individual's absolute treatment benefit, or replace a multidisciplinary decision. Confirm the stroke mechanism, exclude alternative causes, review imaging quality and contraindications, and discuss the benefits and harms of closure with the patient.